HIGHLIGHTS
- who: Shaheer Khan from the University of Pittsburgh Medical Center, United States have published the paper: Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy, in the Journal: (JOURNAL)
- what: The primary outcome of this study was to assess recurrence-free survival (RFS) of patients with high-risk UM who received adjuvant crizotinib. The aim of this phase II, single-stage trial was to determine the 32 months RFS rate in patients with uveal melanoma. By using this study design, the trial demonstrated that there was also a lack of benefit not just compared . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.